|
INVESTMENT HIGHLIGHTS
Why Upstream?
Opportunity
- Diseases targeted have large market sizes & the need for new drugs
High Profit Ration Business Model
- Easily expandable pipeline using Upstream’s proprietary low risk/low cost drug development program
- Artificial intelligence based process effectively generates & screens potential drug candidates quickly and cheaply
- Accelerated drug discovery process will lead to achieving milestones faster
Priority Review Vouchers
- To offer incentives for tropical disease research, the FDA will accelerate drug application review by seven months AND provide the researching company a tradable voucher for similar priority review for a second non-tropical disease drug
- This provides an estimated benefit to a Big Pharma of between $1.5 billion to $5 billion over the lifetime of the drug and sets a floor value of a drug at $300 million (NPV) and effectively gives Upstream a US market for our drug research.
|
|
